Detailed company information
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Jul 30, 2026
Earnings Transcript for 2026 - Q1Released: Apr 28, 2026
Earnings Transcript for 2025 - Q4Released: Feb 24, 2026
Earnings Transcript for 2025 - Q3Released: Nov 04, 2025
Earnings Transcript for 2025 - Q2Released: Aug 06, 2025
Earnings Transcript for 2025 - Q1Released: Apr 30, 2025
Earnings Transcript for 2024 - Q4Released: Feb 26, 2025
Earnings Transcript for 2024 - Q3Released: Nov 04, 2024
Earnings Transcript for 2024 - Q2Released: Jul 31, 2024
Earnings Transcript for 2024 - Q1Released: May 09, 2024
Earnings Transcript for 2023 - Q4Released: Feb 28, 2024
Earnings Transcript for 2023 - Q3Released: Nov 08, 2023
Earnings Transcript for 2023 - Q2Released: Aug 08, 2023
Earnings Transcript for 2023 - Q1Released: May 12, 2023
Earnings Transcript for 2022 - Q4Released: Feb 27, 2023
Earnings Transcript for 2022 - Q3Released: Nov 03, 2022
Earnings Transcript for 2022 - Q2Released: Aug 07, 2022
Earnings Transcript for 2022 - Q1Released: May 05, 2022
Earnings Transcript for 2021 - Q4Released: Feb 24, 2022
Earnings Transcript for 2021 - Q3Released: Oct 28, 2021
Earnings Transcript for 2021 - Q2Released: Jul 30, 2021
Earnings Transcript for 2021 - Q1Released: May 05, 2021
Earnings Transcript for 2020 - Q4Released: Feb 24, 2021
Earnings Transcript for 2020 - Q3Released: Oct 29, 2020
CSTL Castle Biosciences, Inc.